CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy

AIDS

Volumn 25, Issue 14, 2011, Pages 1747-1751

  Ellis, Ronald J ^a   Badiee, Jayraan ^a   Vaida, Florin ^a   Letendre, Scott ^a   Heaton, Robert K ^a   Clifford, David ^b   Collier, Ann C ^c   Gelman, Benjamin ^d   McArthur, Justin ^e   Morgello, Susan ^f   McCutchan, J Allen ^a   Grant, Igor ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CD4 nadir; combination antiretroviral therapy; HIV associated neurocognitive disorders; neurocognitive impairment

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; APTITUDE TEST; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4 NADIR; COGNITIVE DEFECT; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COGNITION DISORDERS; COHORT STUDIES; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; VIRAL LOAD;

EID: 80052412081     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834a40cd     Document Type: Article

References (8)

1. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 2008; 24:1301-1307.
2. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21:1915-1921. (Pubitemid 47329768)
3. Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol 2005; 11:265-273. (Pubitemid 41122414)
4. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75:2087-2096.
5. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69:1789-1799. (Pubitemid 350059308)
6. Kalichman SC, Rompa D, Cage M. Reliability and validity of selfreported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STD AIDS 2000; 11:579-585.
7. Valcour V, Yee P, Williams AE, Shiramizu B, Watters M, Selnes O, et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection-The Hawaii Aging with HIV Cohort. J Neurovirol 2006; 12:387-391. (Pubitemid 44650051)
8. Letendre S,Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al., CHARTER Group. Validation of the CNS penetrationeffectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.